ArticleNature communications2021
Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 47 citations in OpenAlex.
- Molecular Signature and miRNA Pattern of CD4 + T Lymphocytes in Plaque Psoriasis.Clinical reviews in allergy & immunology · 2026Review
- Inflammatory Biomarkers for Assessing Treatment Response in Psoriasis: A Narrative Review.International journal of molecular sciences · 2026Review
- Gngt2 promotes inflammatory dendritic cell programming through an ATG5-NF-κB signaling axis in neutrophilic asthma.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- SPT6 maintains epidermal homeostasis by inhibiting an NF-κB-positive feedback loop to prevent excessive inflammation.Cellular & molecular immunology · 2026Article
- Transcriptomic profiling and machine learning uncover gene signatures of psoriasis endotypes and disease severity.Communications medicine · 2026Article
- Single-Cell RNA Sequencing Revealing Dysregulated Perturbations of Tregs in Psoriasis and Construction of a Treg-Related Diagnostic Model via a 101- Combination Machine Learning Computational FrameworkEndocrine, metabolic & immune disorders drug targets · 2026Article
- Baseline Th17/Tc17 and LAG-3 levels serve as candidate exploratory markers for early ixekizumab response in psoriasis.Frontiers in immunology · 2026Article
- Advancing Precision Medicine in Inflammatory Skin Disease.American journal of clinical dermatology · 2025Review
- Imiquimod promotes Th1 and Th17 responses via NF-κB-driven IL-12 and IL-6 production in anExperimental and therapeutic medicine · 2025Article
- Psoriasis: A Multidimensional Review of Onset, Progression, Treatment, and the Evolution of Disease Models.Molecular diagnosis & therapy · 2025Review
- Circulating CD8 T cells from patients with mild-to-moderate psoriasis are functionally impaired.Frontiers in immunology · 2025Article
- The Role of Metabolic Syndrome in Psoriasis Treatment Response: A One-Year Comparative Analysis of PASI Progression.Diagnostics (Basel, Switzerland) · 2024Article
- RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis.Cancer discovery · 2024Article
- Targeting STING in dendritic cells alleviates psoriatic inflammation by suppressing IL-17A production.Cellular & molecular immunology · 2024Article
- The Immunology of Psoriasis-Current Concepts in Pathogenesis.Clinical reviews in allergy & immunology · 2024Review
- The CD147 expression in CD4Clinical and translational medicine · 2024Article
- Signaling pathways and targeted therapies for psoriasis.Signal transduction and targeted therapy · 2023Review
- Transcutaneous Immunotherapy for RNAi: A Cascade-Responsive Decomposable Nanocomplex Based on Polyphenol-Mediated Framework Nucleic Acid in Psoriasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Assessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology.The Journal of investigative dermatology · 2023Review
- Gene Ontology Analysis Highlights Biological Processes Influencing Responsiveness to Biological Therapy in Psoriasis.Pharmaceutics · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
21 authors at 7 institutions in 2 countries.
Funding
Abstract
Biologic therapies have transformed the management of psoriasis, but clinical outcome is variable leaving an unmet clinical need for predictive biomarkers of response. Here we perform in-depth immunomonitoring of blood immune cells of 67 patients with psoriasis, before and during therapy with the anti-TNF drug adalimumab, to identify immune mediators of clinical response and evaluate their predictive value. Enhanced NF-κBp65 phosphorylation, induced by TNF and LPS in type-2 dendritic cells (DC) before therapy, significantly correlates with lack of clinical response after 12 weeks of treatment. The heightened NF-κB activation is linked to increased DC maturation in vitro and frequency of IL-17
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.